Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

CardioCell

- PMLiVE

ASH 2025: where Magic Kingdom met the spirit of Andor

At ASH 2025, bold science and immersive experience bumped shoulders with a clear call to fight for patients

- PMLiVE

Why Sleep Health is the Missing Link in Women’s Wellness

While obstructive sleep apnea (OSA) affects approximately 32% of US adults—nearly 80 million people—it remains an "epidemic hiding in plain sight". Perhaps most staggering is that 90% of women with...

Medscape Education

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

McNamara’s Fallacy

Why marketing science is harder than you think

Photo of Tim Wright plus title of talk

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Alzheimer’s disease – the future of diagnosis and treatment in Europe

Recognising symptoms early and acting quickly can make a real difference to the lives of patients

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Skyhawk Therapeutics’ SKY-0515 shows positive results in Huntington’s disease

Huntington’s disease affects over 40,000 patients in the US and hundreds of thousands globally

- PMLiVE

Clinical trials on dementia: bridging access and innovation

Addressing the significant challenges surrounding the accessibility and availability of clinical trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links